Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 270

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 270
---
 non-cashadjustments totaling $9.5 million, which were primarily related to share-based compensation expense, discount amortization on short-term investments, lease expense, and depreciation and amortization expense. For the year ended December 31, 2022, cash used in operating activities was $49.6 million and resulted from (i) our net loss of $60.5 million, and (ii) a $1.8 million net increase in our operating assets and liabilities, primarily driven by an increase in accounts receivable, prepaid expenses, inventory related to the commercial launch of FYARRO in February 2022, and accrued expenses; offset by a decrease in accounts payable, and (iii) $12.7 million in non-cashadjustments, which were primarily related to share-based compensation expense, the impairment of the contract intangible asset, and depreciation and amortization expense. - 191 -

Investing Activities

Cash provided by investing activities for the nine months ended September 30, 2024 was $12.1 million related to maturities of short-term investments
of $50.0 million, offset by purchases of short-term investments of $36.5 million, and fixed assets of $1.5 million.

Cash provided by
investing activities for the nine months ended September 30, 2023 was $79.6 million related to maturities of short-term investments of $133.3 million, offset by purchases of short-term investments of $50.5 million, and fixed
assets of $3.2 million.

Cash provided by investing activities for the year ended December 31, 2023 related to maturities of short-term
investments of $151.6 million, offset by purchases of fixed assets of $4.0 million and short-term investments of $64.4 million.

Cash used
in investing activities for the year ended December 31, 2022 related to purchases of short-term investments of $145.2 million offset by maturities of $12.8 million.

Financing Activities

Cash provided by financing
activities for the nine months ended September 30, 2024 was $0.1 million related to the purchase of common stock under the employee stock purchase plan offset by financing costs related to the Sales Agreement.

Cash provided by financing activities for the nine months ended September 30, 2023 was $0.2 million related to the issuance of common stock under
the employee stock purchase plan and exercise of stock options offset